MarketBeat
05 Nov 2026, 00:30 UTC · 1h ago
Adaptive Biotechnologies Q3 Earnings Call Highlights
Impact · against what's priced in
Adaptive Biotechnologies shows strong momentum in clinical clonoSEQ adoption and pharma backlog, coupled with a strategic move to spin off its Immune Medicine business. The guidance raise and Q3 net income are positive, though the lack of full-year GAAP profitability limits the immediate upside.
- ADPT+0.70
No priced-in read yet
- In context
Revenue grew 39% YoY to $83.9M, and the company raised full-year MRD revenue guidance to a midpoint of $282M. The announcement of a planned separation of the Immune Medicine business via Morgan Stanley creates a potential value catalyst.
Read from the article alone
